3 ms·

There was just an announcement of major delays in production and availability relating to the supply chain problems going on. More generally, I'm skeptical that

There was just an announcement of major delays in production and availability relating to the supply chain problems going on. More generally, I'm skeptical that it's advisable to continue administering vaccines which target the spike protein of the original Wuhan strain.

tjr 5y ago
Referring to the Politico article based on the anonymous source? Not sure about that; Novavax immediately put out a release today that they are still on target to submit for approval in various countries yet this year. Agreed, I'm not sure of the value of continuing to target the original virus, but it sounds like Novavax offers decent protection against known variants also. More interestingly, their vaccine directly exposes you to the spike protein, rather than telling your body to fabricate it.
- AndrewBissell 5y ago
  Yeah it definitely seems less risky than the mRNA/adenoviral-vector approach. I know a guy in the Phase 3 trials who had some really bad side effects from the shots, but they only lasted a day. Unfortunately now he's stuck because the mandates all require one of the authorized vaccines, and there's essentially no data on whether it would be safe for him to take one after Novavax.
  - stbenjam 5y ago
    The CDC guidelines explicitly state clinical trial participants are ok for the mandate. My company has a mandate and I’m fine since I was part of the AstraZeneca trial.
  - tjr 5y ago
    I have heard of companies accepting Novavax trial participants as meeting the mandate requirements. Might be worth asking. Or if he is needing a booster shot... yeah, that's a little harder right now. I think some trial participants (in England?) were approved for taking a different vaccine as a booster, but if can possibly hold out, waiting for more Novavax seems to make more sense to me.

3 ms·

There was just an announcement of major delays in production and availability relating to the supply chain problems going on. More generally, I'm skeptical that

by AndrewBissell 5y ago

tjr 5y ago
Referring to the Politico article based on the anonymous source? Not sure about that; Novavax immediately put out a release today that they are still on target to submit for approval in various countries yet this year. Agreed, I'm not sure of the value of continuing to target the original virus, but it sounds like Novavax offers decent protection against known variants also. More interestingly, their vaccine directly exposes you to the spike protein, rather than telling your body to fabricate it.
- AndrewBissell 5y ago
  Yeah it definitely seems less risky than the mRNA/adenoviral-vector approach. I know a guy in the Phase 3 trials who had some really bad side effects from the shots, but they only lasted a day. Unfortunately now he's stuck because the mandates all require one of the authorized vaccines, and there's essentially no data on whether it would be safe for him to take one after Novavax.
  - stbenjam 5y ago
    The CDC guidelines explicitly state clinical trial participants are ok for the mandate. My company has a mandate and I’m fine since I was part of the AstraZeneca trial.
  - tjr 5y ago
    I have heard of companies accepting Novavax trial participants as meeting the mandate requirements. Might be worth asking. Or if he is needing a booster shot... yeah, that's a little harder right now. I think some trial participants (in England?) were approved for taking a different vaccine as a booster, but if can possibly hold out, waiting for more Novavax seems to make more sense to me.